Table 1.
Characteristics of atrial fibrillation patients by anticoagulant use, MarketScan Databases, 2009 to 2012
| New Users | Switchers | Pooled (New Users and Switchers) |
||||
|---|---|---|---|---|---|---|
|
| ||||||
| Dabigatran | Matched | Dabigatran | Matched | Rivaroxaban | Matched | |
| User | Warfarin User | User | Warfarin User | User | Warfarin User | |
| Age, years | 68.5±12.3 | 70.8±12.1 | 70.9±11.3 | 71.5±11.4 | 70.4±12.0 | 72.5±12.2 |
| Female, % | 36.2 | 38.8 | 37.9 | 38.0 | 39.8 | 41.2 |
| Comorbidities, % | ||||||
| Hypertension | 75.2 | 72.9 | 82.0 | 80.2 | 85.6 | 84.7 |
| Diabetes | 28.6 | 32.1 | 32.2 | 33.8 | 30.7 | 35.4 |
| Myocardial infarction | 7.6 | 9.5 | 7.6 | 9.2 | 10.5 | 11.7 |
| Heart failure | 24.3 | 30.4 | 35.2 | 36.6 | 31.5 | 39.3 |
| Ischemic stroke/TIA | 20.6 | 22.3 | 25.4 | 24.0 | 26.3 | 30.9 |
| Hemorrhagic stroke | 0.7 | 1.1 | 1.1 | 1.4 | 1.3 | 2.1 |
| Renal disease | 7.6 | 12.9 | 10.0 | 13.0 | 11.2 | 16.0 |
| PAD | 15.5 | 18.0 | 19.8 | 20.3 | 21.4 | 25.6 |
| Dementia | 1.0 | 2.0 | 1.4 | 2.1 | 1.7 | 3.0 |
| Chronic pulmonary disease | 24.8 | 28.0 | 28.9 | 30.6 | 34.0 | 36.0 |
| Liver disease | 4.8 | 4.9 | 5.8 | 5.7 | 7.5 | 7.7 |
| Malignancy | 13.4 | 14.7 | 15.2 | 16.4 | 15.8 | 19.3 |
| Depression | 7.8 | 9.2 | 8.5 | 9.6 | 12.2 | 12.3 |
| Hematological disorders | 9.2 | 14.1 | 19.0 | 20.0 | 17.0 | 22.5 |
| Metastatic cancer | 1.6 | 2.3 | 1.4 | 2.2 | 1.9 | 2.5 |
| Alcohol abuse | 0.4 | 0.5 | 0.5 | 0.5 | 0.6 | 0.5 |
| GI bleed | 7.6 | 8.3 | 10.4 | 11.4 | 13.2 | 14.5 |
| Other bleed | 3.6 | 5.0 | 7.9 | 8.4 | 7.6 | 9.5 |
| CHADS2 score | 2.0±1.4 | 2.2±1.5 | 2.4±1.4 | 2.4±1.5 | 2.4±1.5 | 2.7±1.6 |
| Initial (first) dose of novel oral anticoagulant*, % | ||||||
| Rivaroxaban | ||||||
| 10 mg | – | – | – | – | 15.7 | – |
| 15 mg | – | – | – | – | 15.2 | – |
| 20 mg | – | – | – | – | 69.2 | – |
| Dabigatran | ||||||
| 75 mg | 8.3 | – | 6.6 | – | – | – |
| 150 mg | 91.7 | – | 93.4 | – | – | – |
| Prior procedures | ||||||
| Cardiac | 69.0 | 70.9 | 75.9 | 78.2 | 81.3 | 80.2 |
| Vascular | 4.0 | 7.9 | 5.3 | 6.9 | 6.9 | 9.3 |
| Gastrointestinal | 35.3 | 32.4 | 41.8 | 39.8 | 51.9 | 50.1 |
| Neurological | 15.4 | 15.6 | 19.4 | 17.2 | 29.3 | 22.6 |
| Medications | ||||||
| Digoxin | 14.9 | 16.2 | 28.9 | 27.6 | 21.9 | 25.3 |
| Clopidogrel | 14.0 | 12.0 | 10.8 | 10.1 | 15.7 | 13.0 |
| Antiplatelets | 2.1 | 2.0 | 1.5 | 1.6 | 2.9 | 2.3 |
| Angiotensin-converting-enzyme inhibitors | 36.0 | 37.6 | 42.5 | 43.3 | 40.3 | 43.9 |
| Angiotensin receptor blockers | 23.5 | 20.5 | 28.1 | 23.9 | 29.3 | 25.7 |
| β-blockers | 71.1 | 64.8 | 79.4 | 76.2 | 77.6 | 76.4 |
| Calcium channel blockers | 41.7 | 39.4 | 48.9 | 44.4 | 48.3 | 46.5 |
| Anti-arrhythmias | 29.4 | 20.4 | 39.3 | 29.1 | 41.5 | 29.4 |
| Statins | 54.3 | 51.7 | 64.2 | 61.5 | 61.3 | 62.5 |
| Diabetes medications | 21.5 | 23.7 | 24.0 | 24.8 | 21.2 | 24.8 |
Values correspond to mean ± standard deviation or percentage
*
A small number of patients (<0.1%) had multiple prescriptions with conflicting medication strengths on the same day; the most common dose was assigned, 150 mg and 20 mg for dabigatran and rivaroxaban, respectively.
TIA, transient ischemic attack; PAD, peripheral arterial disease; GI, gastrointestinal.